VivoSeq
Other

Immunization

0

Pipeline Programs

4

Active Trials

7

Companies Involved

Immunization is an early-stage landscape with 0 programs across 7 companies. The most active players are GSK, Livzon Pharmaceutical Group Inc., Sanofi.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

3/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

60

clinical trials

Completed47 · 78%
Unknown status6 · 10%
Active, not recruiting3 · 5%
Suspended1 · 2%
Terminated1 · 2%
Not yet recruiting1 · 2%
Other1 · 2%

Trial Activity

60 trials

Maternal Tdap Immunization in Guatemala
Completed·EEmory University·Phase 2·NCT02301702·286 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)